Log in

Relevant bibliographies by topics / Oncolytic Viral Therapy

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Oncolytic Viral Therapy'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Oncolytic Viral Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Oncolytic Viral Therapy"

1

Zurkiya, Omar, and Suvranu Ganguli. "Viral Oncolytic Therapy." Journal of Clinical Interventional Radiology ISVIR 01, no. 02 (2017): 096–99. http://dx.doi.org/10.1055/s-0037-1602389.

Full text

Abstract:

AbstractViral oncolysis broadly refers to the use of modified viruses to infect and subsequently lyse tumor cells. This concept arises from the observation that viral replication is itself effective in destroying tumor cells. This effect is then amplified by reinfection of adjacent tumor cells by the progeny virion released from lysed tumor cells. Herpes simplex virus 1 (HSV-1) has been the primary focus of current efforts in viral oncolysis. It is a double-stranded DNA virus that is a ubiquitous pathogen transmitted by direct mucosal contact. HSV-1 possesses several features well suited to vi

APA, Harvard, Vancouver, ISO, and other styles

2

Hackethal, Veronica. "Oncolytic Viral Therapy." Oncology Times 42, no. 11 (2020): 1–9. http://dx.doi.org/10.1097/01.cot.0000669692.29645.ac.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Karadimas, Thomas, Thien Huong Huynh, Chloe Chose, et al. "Oncolytic Viral Therapy in Osteosarcoma." Viruses 16, no. 7 (2024): 1139. http://dx.doi.org/10.3390/v16071139.

Full text

Abstract:

Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells. Various oncolytic viruses (OVs), such as adenovirus, herpes simplex virus, and measles virus, have demonstrated efficacy in

APA, Harvard, Vancouver, ISO, and other styles

4

Vengadaragava Chary, Krishnan, and Anish Bharatwaj. "ONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS." Asian Journal of Pharmaceutical and Clinical Research 10, no. 10 (2017): 96. http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19265.

Full text

Abstract:

Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase

APA, Harvard, Vancouver, ISO, and other styles

5

Kim, Sang-In, Shyambabu Chaurasiya, Anthony K. Park, et al. "Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models." International Journal of Molecular Sciences 21, no. 19 (2020): 7326. http://dx.doi.org/10.3390/ijms21197326.

Full text

Abstract:

Oncolytic viroimmunotherapy is an exciting modality that can offer lasting anti-tumor immunity for aggressive malignancies like colon cancer. The impact of oncolytic viruses may be extended by combining them with agents to prime a tumor for viral susceptibility. This study investigates vitamin D analogue as an adjunct to oncolytic viral therapy for colon cancer. While vitamin D (VD) has historically been viewed as anti-viral, our in vitro investigations using human colon cancer cell lines showed that VD does not directly inhibit replication of recombinant chimeric poxvirus CF33. VD did restric

APA, Harvard, Vancouver, ISO, and other styles

6

Haddad, Dana, and Yuman Fong. "Molecular imaging of oncolytic viral therapy." Molecular Therapy - Oncolytics 1 (2014): 14007. http://dx.doi.org/10.1038/mto.2014.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Parker, Jacqueline Nuss, David F. Bauer, James J. Cody, and James M. Markert. "Oncolytic viral therapy of malignant glioma." Neurotherapeutics 6, no. 3 (2009): 558–69. http://dx.doi.org/10.1016/j.nurt.2009.04.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Advani, Sunil J., James J. Mezhir, Bernard Roizman, and Ralph R. Weichselbaum. "ReVOLT: radiation-enhanced viral oncolytic therapy." International Journal of Radiation Oncology*Biology*Physics 66, no. 3 (2006): 637–46. http://dx.doi.org/10.1016/j.ijrobp.2006.06.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Rahal, Ahmad, and Benjamin Musher. "Oncolytic viral therapy for pancreatic cancer." Journal of Surgical Oncology 116, no. 1 (2017): 94–103. http://dx.doi.org/10.1002/jso.24626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alvarez-Breckenridge, Christopher A., Jianhua Yu, Balveen Kaur, Michael A. Caligiuri, and E. Antonio Chiocca. "Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells." Advances in Virology 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/702839.

Full text

Abstract:

Despite active research in virotherapy, this apparently safe modality has not achieved widespread success. The immune response to viral infection appears to be an essential factor that determines the efficacy of oncolytic viral therapy. The challenge is determining whether the viral-elicited immune response is a hindrance or a tool for viral treatment. NK cells are a key component of innate immunity that mediates antiviral immunity while also coordinating tumor clearance. Various reports have suggested that the NK response to oncolytic viral therapy is a critical factor in premature viral clea

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Oncolytic Viral Therapy"

1

Hardcastle, Jayson James. "Vstat120 modulates inhibits oncolytic viral therapy induced angiogenesis and innate pro-inflamatory response, augmenting oncolytic viral thereapy of glioblastom multiforme." The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1305920551.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Watson, Margaret. "Characterizing a Novel Viral Sensitizer BI-D1870." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39364.

Full text

Abstract:

Oncolytic viruses (OVs) are an emerging cancer therapy that use an oncotropic virus to selectively infect and kill cancer cells, as well as stimulate long-lasting anti-tumor immune responses. In order to achieve high therapeutic efficacy, OVs need sufficient replication within the tumor tissue to mediate these effects. However, OV’s infectivity varies between different tumors and the host’s immune system can rapidly clear the virus, hampering treatment efficiency. Oncolytic virus sensitizers are chemical compounds that specifically enhance OV’s infectivity and efficacy. In our lab, I found tha

APA, Harvard, Vancouver, ISO, and other styles

3

Moussavi, Maryam. "Pre-clinical treatment of prostate cancer using targeted oncolytic viral therapy." Thesis, University of British Columbia, 2011. http://hdl.handle.net/2429/33980.

Full text

Abstract:

Prostate cancer is the most prevalent non-skin malignancy and the second leading cause of cancer-related mortality in North American men. Current therapies for patients with locally advanced or metastatic prostate cancer are largely palliative and non-curative. Oncolytic viral-therapy provides a new approach to efficiently target and kill cancer cells while sparing normal cells. Vesicular Stomatitis Virus (VSV) is an oncolytic virus, which can infect and kill cells that have defects in their cellular anti-viral interferon (IFN) response. In this study, enhanced IFN-sensitive VSV(AV3) strain w

APA, Harvard, Vancouver, ISO, and other styles

4

Meisen, Walter Hans. "Improving Oncolytic Viral Therapy for Primary and Metastatic Tumors in the Brain." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1429187113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Le, Thu-Ha. "Protein dynamics in responder and non-responder solid tumor xenografts during oncolytic viral therapy." kostenfrei, 2008. http://www.opus-bayern.de/uni-wuerzburg/volltexte/2009/3201/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

FOSCHINI, Maria Giovanna. "Use of miRNA target sequences to control essential genes of HSV1-based oncolytic vectors." Doctoral thesis, Università degli studi di Ferrara, 2012. http://hdl.handle.net/11392/2389272.

Full text

Abstract:

The principal aim of this research is to design a new oncolytic vector based on herpes simplex virus type 1 (HSV-1) that can selectively destroy the cancer cells, while reducing the risk of toxicity in surrounding tissue or in other tissues. One approach to design these vectors, in order to obtain a controlled viral replication and their spread only inside the tumor mass, is taking advantage of unique tissue-associated patterns of expression of microRNAs (miRNA). Recent studies have shown that some miRNAs are overexpressed and some are down-regulated in several cancer cells, compared with thei

APA, Harvard, Vancouver, ISO, and other styles

7

Abate-Daga, Daniel. "Estudios de factores que condicionan la sensibilidad del tratamiento con TK/GCV. Diseño de estrategias combinadas para potenciar la citotoxicidad de TK/GCV: Silenciamiento de genes antiapópticos y virus oncolíticos armados con TK." Doctoral thesis, Universitat Pompeu Fabra, 2009. http://hdl.handle.net/10803/7135.

Full text

Abstract:

El sistema TK/GCV es, problamente, la estrategia suicida mejor caracterizada hasta el momento. No obstante, se desconocen muchos aspectos relacionados con su mecanismo de acción. Con el objetivo de indentificar condicionantes de la respuesta TK/GCV, realizamos un estudio comparativo de la expresión de genes y de las vías de señalización que se activan en células sensibles y en células resistentes al tratamiento. Así, pudimos asociar la actividad de la quinasa Chk1, y la expresión de genes involucrados en el control del ciclo celular, con una mayor respuesta al sistema suicida. Así mismo, deter

APA, Harvard, Vancouver, ISO, and other styles

8

Strauss, Robert. "Analysis of resistance of primary ovarian cancer cells to viral oncolysis." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2010. http://dx.doi.org/10.18452/16163.

Full text

Abstract:

Auf Adenoviren (Ads) basierende Vektoren wurden als ein gezielter Anti-Krebs-Wirkstoff entwickelt, der erfolgversprechende Resultate in prä-klinischen Studien erzielen konnte. Solche onkolytischen Ads sind zwar in klinischen Studien generell als sicher eingestuft worden, konnten jedoch die therapeutischen Erwartungen nicht erfüllen. In dieser Doktorarbeit konnte, unter Verwendung der Genexpressionsprofile von Ovarialkarzinom-Zellen, der epitheliale Phänotyp als Hindernis für allgemein verwendete onkolytische Ads, die auf den Coxsackie- und Adenovirusrezeptor (CAR) oder CD46 ausgerichtet sind,

APA, Harvard, Vancouver, ISO, and other styles

9

Altomonte, Jennifer [Verfasser]. "Optimization of oncolytic viral therapy for hepatocellular carcinoma / Jennifer Altomonte." 2010. http://d-nb.info/101094097X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Le, Thu Ha. "Protein dynamics in responder and non-responder solid tumor xenografts during oncolytic viral therapy." Doctoral thesis, 2008. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-32016.

Full text

Abstract:

VACV GLV-1h68 was reported as a diagnostic/therapeutic vector which enters, replicates in, and reveals the locations of tumors in mice. Furthermore, the effect on tumor colonization, on tumor growth, regression and eradication by VACV GLV-1h68 without the need of any known genes with anti-tumoral activities was determined. To investigate differential protein expression between infected tumor cells and corresponding tumors, as well as between infected tumor cells, between infected tumors, proteomics is particularly used, possibly contributing to the understanding oncolytic ability on the protei

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Oncolytic Viral Therapy"

1

1958-, Harrington Kevin J., Pandha Hardev, and Vile Richard G, eds. Viral therapy of cancer. John Wiley & Sons, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brenner, Malcolm K., and Mien-chie Hung. Cancer gene therapy by viral and non-viral vectors. Wiley Balckwell, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

(Editor), Richard G. Vile, and Hardev Pandha (Editor), eds. Viral Therapy of Cancer. John Wiley & Sons, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Limited, John, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Oncolytic Viral Therapy"

1

Thirukkumaran, Chandini, and Don G. Morris. "Oncolytic Viral Therapy Using Reovirus." In Gene Therapy of Cancer. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-561-9_31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Thirukkumaran, Chandini, and Don G. Morris. "Oncolytic Viral Therapy Using Reovirus." In Methods in Molecular Biology. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2727-2_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lamfers, Martine L. M., Therese Visted, and E. Antonio Chiocca. "Oncolytic Viral Therapy for Glioma." In Progress in Neurological Surgery. KARGER, 2005. http://dx.doi.org/10.1159/000084480.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Miura, John T., and Jonathan S. Zager. "Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants." In Cancer Regional Therapy. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28891-4_35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Javed, Mohd, and Sisir Nandi. "Oncolytic Viral Therapy: A Promising Approach in Cancer Treatment." In Global Trends in Health, Technology and Management. Springer Nature Switzerland, 2024. https://doi.org/10.1007/978-3-031-75457-9_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Spiesschaert, Bart, and Saurabh Gautam. "Oncolytic Viruses and Viral Gene Therapy Vectors: Principles of Safety." In Bioprocess and Analytics Development for Virus-based Advanced Therapeutics and Medicinal Products (ATMPs). Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-28489-2_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Full text

Abstract:

AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, m

APA, Harvard, Vancouver, ISO, and other styles

8

Ayyildiz, Orhan, and Yusuf Hekimoglu. "What Is Immunotherapy and History of Immunotherapy in Cancers." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.1.

Full text

Abstract:

Immunotherapy, a transformative cancer treatment, harnesses the immune system’s inherent ability to combat neoplastic cells. Ancient medicine hinted at immunological principles, recognizing natural disease resistance and the body’s defensive capabilities. Over time, the understanding of the immune system evolved, with key contributions from early thinkers like Ibn Sina and later scientific pioneers like Ilya Mechnikov. The immune system, comprising innate and adaptive components, is vital in defending against pathogens and regulating cell proliferation, including cancerous cells. The concept o

APA, Harvard, Vancouver, ISO, and other styles

9

"Newcastle Disease Virus: Its Oncolytic Properties." In Viral Therapy of Human Cancers. CRC Press, 2004. http://dx.doi.org/10.1201/b14180-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Measles Virus: Improving Natural Oncolytic Properties by Genetic Engineering." In Viral Therapy of Human Cancers. CRC Press, 2004. http://dx.doi.org/10.1201/b14180-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Oncolytic Viral Therapy"

1

Barreto, Everton Rodrigo, Rosana Maria Faria Vador, and Thalita Martins Ferraz Meneses. "Nurse performance in viral oncolytic therapy." In III SEVEN INTERNATIONAL MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/seveniiimulti2023-084.

Full text

Abstract:

Introduction: Viral oncolytic therapy (VOT) is an emerging approach in cancer treatment, which is based on the selective replication of a viral vector inside cancer cells, triggering the death of tumor cells by lysis and the spread of new viral particles to the remaining adjacent malignant cells. However, special care is needed from nurses to manage immune-mediated side effects and provide support and education to patients and their families during treatment. Objectives: To survey the nurse's performance in the face of VOT; propose a model of Systematization of Nursing Care (SNC) with the main

APA, Harvard, Vancouver, ISO, and other styles

2

Elshourbagy, Tarek, and James Robert Brašić. "Oncolytic Viral Therapy with Gravity Approaching Zero to Ameliorate Glioblastoma Multiforme." In IECC 2024. MDPI, 2024. http://dx.doi.org/10.3390/proceedings2024100024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Alvarez-Breckenridge, Christopher A., Jianhua Yu, Jason Pradarelli, et al. "Abstract 1514: Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1514.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mostafa, Ahmed, Kathy Gratton, Keith A. Lawson, Zhong-Qiao Shi, Chandini Thirukkumaran, and Don G. Morris. "Abstract A12: PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Elshourbagy, Tarek, and James Robert Brašić. "Amelioration of Glioblastoma Multiforme via the Combination of Simulated Microgravity and Oncolytic Viral Therapy." In International Electronic Conference on Cancers: New Targets for Cancer Therapies. MDPI, 2023. http://dx.doi.org/10.3390/iecc2023-14219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ogata, Hisanobu, Beibei Wang, Shoei Miyamoto, et al. "Abstract 4779: Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4779.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ogata, Hisanobu, Beibei Wang, Shoei Miyamoto, et al. "Abstract 4779: Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4779.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

D’Souza, Alicia, Ryuhjin Ahn, GBM TeamLab, and Forest White. "1368 Characterizing changes in antigen presentation of glioblastoma tumors in response to oncolytic viral therapy." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.1368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Contag, Pamela R. "Abstract CT155: Design of a dose escalation phase 1/2 trial for a novel combined cell and oncolytic viral therapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liu, Jianrui, Jason Spurrel, Zhong Qiao Shi, WenQian Chen, and Don G. Morris. "Abstract 5355: Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Oncolytic Viral Therapy"

1

Martuza, Robert L. Immunologic Approaches for Oncolytic Viral Therapy of Prostate Cancer. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada433864.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!